167 related articles for article (PubMed ID: 10331745)
21. Chromosome 3p14 homozygous deletions and sequence analysis of FRA3B.
Boldog F; Gemmill RM; West J; Robinson M; Robinson L; Li E; Roche J; Todd S; Waggoner B; Lundstrom R; Jacobson J; Mullokandov MR; Klinger H; Drabkin HA
Hum Mol Genet; 1997 Feb; 6(2):193-203. PubMed ID: 9063739
[TBL] [Abstract][Full Text] [Related]
22. The role of deletions at the FRA3B/FHIT locus in carcinogenesis.
Huebner K; Druck T; Siprashvili Z; Croce CM; Kovatich A; McCue PA
Recent Results Cancer Res; 1998; 154():200-15. PubMed ID: 10027001
[TBL] [Abstract][Full Text] [Related]
23. The role of the FHIT/FRA3B locus in cancer.
Huebner K; Garrison PN; Barnes LD; Croce CM
Annu Rev Genet; 1998; 32():7-31. PubMed ID: 9928473
[TBL] [Abstract][Full Text] [Related]
24. Aberrant fragile histidine triad gene transcripts in primary hepatocellular carcinoma and liver cirrhosis.
Gramantieri L; Chieco P; Di Tomaso M; Masi L; Piscaglia F; Brillanti S; Gaiani S; Valgimigli M; Mazziotti A; Bolondi L
Clin Cancer Res; 1999 Nov; 5(11):3468-75. PubMed ID: 10589760
[TBL] [Abstract][Full Text] [Related]
25. The FHIT gene at 3p14.2 is abnormal in breast carcinomas.
Negrini M; Monaco C; Vorechovsky I; Ohta M; Druck T; Baffa R; Huebner K; Croce CM
Cancer Res; 1996 Jul; 56(14):3173-9. PubMed ID: 8764101
[TBL] [Abstract][Full Text] [Related]
26. Expression of FRA16D/WWOX and FRA3B/FHIT genes in hematopoietic malignancies.
Ishii H; Vecchione A; Furukawa Y; Sutheesophon K; Han SY; Druck T; Kuroki T; Trapasso F; Nishimura M; Saito Y; Ozawa K; Croce CM; Huebner K; Furukawa Y
Mol Cancer Res; 2003 Nov; 1(13):940-7. PubMed ID: 14638866
[TBL] [Abstract][Full Text] [Related]
27. Homozygous deletion but not mutation of exons 5 and 8 of the fragile histidine triad (FHIT) gene is associated with features of differentiated thyroid carcinoma.
Yin DT; Wang L; Sun J; Yin F; Yan Q; Shen RL; Gao JX; He G
Ann Clin Lab Sci; 2010; 40(3):267-72. PubMed ID: 20689140
[TBL] [Abstract][Full Text] [Related]
28. Analysis of the fragile histidine triad gene in primary gastric carcinomas and gastric carcinoma cell lines.
Tamura G; Sakata K; Nishizuka S; Maesawa C; Suzuki Y; Iwaya T; Terashima M; Saito K; Satodate R
Genes Chromosomes Cancer; 1997 Sep; 20(1):98-102. PubMed ID: 9290961
[TBL] [Abstract][Full Text] [Related]
29. Aberrant FHIT transcripts in human colorectal cancers.
Lee SH; Lee SH
Res Commun Mol Pathol Pharmacol; 2005; 117-118():153-65. PubMed ID: 18426086
[TBL] [Abstract][Full Text] [Related]
30. Identification of unstable sequences within the common fragile site at 3p14.2: implications for the mechanism of deletions within fragile histidine triad gene/common fragile site at 3p14.2 in tumors.
Corbin S; Neilly ME; Espinosa R; Davis EM; McKeithan TW; Le Beau MM
Cancer Res; 2002 Jun; 62(12):3477-84. PubMed ID: 12067991
[TBL] [Abstract][Full Text] [Related]
31. Altered expression of the fragile histidine triad gene in primary gastric adenocarcinomas.
Lee SH; Kim WH; Kim HK; Woo KM; Nam HS; Kim HS; Kim JG; Cho MH
Biochem Biophys Res Commun; 2001 Jun; 284(3):850-5. PubMed ID: 11396980
[TBL] [Abstract][Full Text] [Related]
32. Structure and expression of the human FHIT gene in normal and tumor cells.
Druck T; Hadaczek P; Fu TB; Ohta M; Siprashvili Z; Baffa R; Negrini M; Kastury K; Veronese ML; Rosen D; Rothstein J; McCue P; Cotticelli MG; Inoue H; Croce CM; Huebner K
Cancer Res; 1997 Feb; 57(3):504-12. PubMed ID: 9012482
[TBL] [Abstract][Full Text] [Related]
33. Aberrant FHIT transcripts in acute myeloid leukaemia.
Lin PM; Liu TC; Chang JG; Chen TP; Lin SF
Br J Haematol; 1997 Dec; 99(3):612-7. PubMed ID: 9401074
[TBL] [Abstract][Full Text] [Related]
34. FHIT and TSG101 in thyroid tumours: aberrant transcripts reflect rare abnormal RNA processing events of uncertain pathogenetic or clinical significance.
McIver B; Grebe SK; Wang L; Hay ID; Yokomizo A; Liu W; Goellner JR; Grant CS; Smith DI; Eberhardt NL
Clin Endocrinol (Oxf); 2000 Jun; 52(6):749-57. PubMed ID: 10848880
[TBL] [Abstract][Full Text] [Related]
35. Molecular analysis of the FHIT gene in human prostate cancer.
Latil A; Bièche I; Fournier G; Cussenot O; Pesche S; Lidereau R
Oncogene; 1998 Apr; 16(14):1863-8. PubMed ID: 9583683
[TBL] [Abstract][Full Text] [Related]
36. Aberrant splicing of the TSG101 and FHIT genes occurs frequently in multiple malignancies and in normal tissues and mimics alterations previously described in tumours.
Gayther SA; Barski P; Batley SJ; Li L; de Foy KA; Cohen SN; Ponder BA; Caldas C
Oncogene; 1997 Oct; 15(17):2119-26. PubMed ID: 9366528
[TBL] [Abstract][Full Text] [Related]
37. Pattern of FHIT gene expression in normal and leukaemic cells.
Yang HW; Piao HY; Taki T; Chen T; Hashizume K; Ohnishi H; Bessho F; Yanagisawa M; Matsuo Y; Hayashi Y
Int J Cancer; 1999 Jun; 81(6):897-901. PubMed ID: 10362136
[TBL] [Abstract][Full Text] [Related]
38. Chromosome 3p14 alterations in lung cancer: evidence that FHIT exon deletion is a target of tobacco carcinogens and asbestos.
Nelson HH; Wiencke JK; Gunn L; Wain JC; Christiani DC; Kelsey KT
Cancer Res; 1998 May; 58(9):1804-7. PubMed ID: 9581816
[TBL] [Abstract][Full Text] [Related]
39. FHIT gene alterations in esophageal cancer and ulcerative colitis (UC).
Zou TT; Lei J; Shi YQ; Yin J; Wang S; Souza RF; Kong D; Shimada Y; Smolinski KN; Greenwald BD; Abraham JM; Harpaz N; Meltzer SJ
Oncogene; 1997 Jul; 15(1):101-5. PubMed ID: 9233782
[TBL] [Abstract][Full Text] [Related]
40. Understanding the mechanisms of FHIT inactivation in cervical cancer for biomarker development.
Lea JS; Ashfaq R; Muneer S; Burbee DG; Miller DS; Minna JD; Muller CY
J Soc Gynecol Investig; 2004 Jul; 11(5):329-37. PubMed ID: 15219888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
